Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0U6BQ
|
||||
Former ID |
DIB001919
|
||||
Drug Name |
Anti-VEGFR2 CD8 cell therapy
|
||||
Synonyms |
Autologous T-lymphocyte cell therapy; Anti-VEGFR2 CD8 cell therapy (cancer)
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1/2 | [523207] | ||
Company |
Pervasis Therapeutics
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [523207], [532072] | |
T-cell surface glycoprotein CD8 | Target Info | Modulator | [523207], [532072] | ||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04514:Cell adhesion molecules (CAMs) | |||||
Antigen processing and presentation | |||||
Hematopoietic cell lineage | |||||
T cell receptor signaling pathway | |||||
Primary immunodeficiency | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
References | |||||
Ref 523207 | ClinicalTrials.gov (NCT01218867) CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer. U.S. National Institutes of Health. | ||||
Ref 532072 | Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.